Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.19
(3.2%)
USD 4.19
(3.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 39.55 Million USD | -5.85% |
| 2022 | 42.01 Million USD | 16.75% |
| 2021 | 35.98 Million USD | -3.89% |
| 2020 | 37.44 Million USD | 8.88% |
| 2019 | 34.38 Million USD | -15.59% |
| 2018 | 40.74 Million USD | -0.99% |
| 2017 | 41.15 Million USD | 24.6% |
| 2016 | 33.02 Million USD | -1.47% |
| 2015 | 33.51 Million USD | -9.17% |
| 2014 | 36.9 Million USD | 15.22% |
| 2013 | 32.02 Million USD | -34.44% |
| 2012 | 48.85 Million USD | -4.48% |
| 2011 | 51.14 Million USD | 11.48% |
| 2010 | 45.87 Million USD | 5.37% |
| 2009 | 43.53 Million USD | 24.13% |
| 2008 | 35.07 Million USD | 24.98% |
| 2007 | 28.06 Million USD | 57.52% |
| 2006 | 17.81 Million USD | 66.66% |
| 2005 | 10.68 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 8.49 Million USD | -9.15% |
| 2024 Q2 | 9.84 Million USD | 15.9% |
| 2023 Q2 | 10.88 Million USD | 18.04% |
| 2023 Q4 | 9.35 Million USD | -7.27% |
| 2023 FY | 39.55 Million USD | -5.85% |
| 2023 Q3 | 10.08 Million USD | -7.37% |
| 2023 Q1 | 9.22 Million USD | 1.11% |
| 2022 Q2 | 10.29 Million USD | -7.84% |
| 2022 Q3 | 11.41 Million USD | 10.82% |
| 2022 FY | 42.01 Million USD | 16.75% |
| 2022 Q4 | 9.12 Million USD | -20.06% |
| 2022 Q1 | 11.17 Million USD | 34.32% |
| 2021 Q4 | 8.31 Million USD | 3.06% |
| 2021 Q3 | 8.07 Million USD | -10.85% |
| 2021 Q2 | 9.05 Million USD | -14.06% |
| 2021 Q1 | 10.53 Million USD | 2.69% |
| 2021 FY | 35.98 Million USD | -3.89% |
| 2020 Q3 | 9.25 Million USD | -3.62% |
| 2020 FY | 37.44 Million USD | 8.88% |
| 2020 Q1 | 8.33 Million USD | -39.1% |
| 2020 Q2 | 9.59 Million USD | 15.21% |
| 2020 Q4 | 10.26 Million USD | 10.93% |
| 2019 FY | 34.38 Million USD | -15.59% |
| 2019 Q1 | 11.9 Million USD | -11.82% |
| 2019 Q4 | 13.67 Million USD | 31.88% |
| 2019 Q3 | 10.37 Million USD | -10.44% |
| 2019 Q2 | 11.58 Million USD | -2.71% |
| 2018 Q1 | 8.58 Million USD | -26.28% |
| 2018 FY | 40.74 Million USD | -0.99% |
| 2018 Q4 | 13.49 Million USD | 58.94% |
| 2018 Q3 | 8.49 Million USD | -16.44% |
| 2018 Q2 | 10.16 Million USD | 18.35% |
| 2017 Q1 | 9.63 Million USD | 6.11% |
| 2017 FY | 41.15 Million USD | 24.6% |
| 2017 Q4 | 11.64 Million USD | 4.04% |
| 2017 Q3 | 11.19 Million USD | 29.19% |
| 2017 Q2 | 8.66 Million USD | -10.06% |
| 2016 Q2 | 7.41 Million USD | -4.17% |
| 2016 Q3 | 8.79 Million USD | 18.57% |
| 2016 Q4 | 9.08 Million USD | 3.29% |
| 2016 FY | 33.02 Million USD | -1.47% |
| 2016 Q1 | 7.73 Million USD | -3.73% |
| 2015 Q2 | 8.9 Million USD | 2.57% |
| 2015 FY | 33.51 Million USD | -9.17% |
| 2015 Q1 | 8.68 Million USD | -6.89% |
| 2015 Q4 | 8.03 Million USD | 1.93% |
| 2015 Q3 | 7.88 Million USD | -11.5% |
| 2014 Q4 | 9.32 Million USD | -4.11% |
| 2014 FY | 36.9 Million USD | 15.22% |
| 2014 Q2 | 9.75 Million USD | 20.47% |
| 2014 Q1 | 8.09 Million USD | -0.81% |
| 2014 Q3 | 9.72 Million USD | -0.22% |
| 2013 FY | 32.02 Million USD | -34.44% |
| 2013 Q4 | 8.15 Million USD | 24.98% |
| 2013 Q1 | 10.25 Million USD | -25.1% |
| 2013 Q2 | 7.08 Million USD | -30.97% |
| 2013 Q3 | 6.52 Million USD | -7.8% |
| 2012 Q1 | 10.25 Million USD | -21.3% |
| 2012 FY | 48.85 Million USD | -4.48% |
| 2012 Q2 | 12.36 Million USD | 20.58% |
| 2012 Q3 | 12.53 Million USD | 1.33% |
| 2012 Q4 | 13.69 Million USD | 9.29% |
| 2011 Q2 | 14.38 Million USD | 34.9% |
| 2011 Q4 | 13.03 Million USD | -0.17% |
| 2011 FY | 51.14 Million USD | 11.48% |
| 2011 Q3 | 13.05 Million USD | -9.28% |
| 2011 Q1 | 10.66 Million USD | -16.76% |
| 2010 Q3 | 12.19 Million USD | 13.51% |
| 2010 FY | 45.87 Million USD | 5.37% |
| 2010 Q4 | 12.81 Million USD | 5.12% |
| 2010 Q1 | 10.13 Million USD | -5.45% |
| 2010 Q2 | 10.73 Million USD | 6.01% |
| 2009 Q2 | 9.82 Million USD | 4.42% |
| 2009 Q1 | 9.4 Million USD | -4.14% |
| 2009 Q3 | 13.59 Million USD | 38.46% |
| 2009 FY | 43.53 Million USD | 24.13% |
| 2009 Q4 | 10.71 Million USD | -21.21% |
| 2008 Q2 | 8.35 Million USD | 0.65% |
| 2008 Q1 | 8.3 Million USD | 11.7% |
| 2008 Q4 | 9.81 Million USD | 14.05% |
| 2008 Q3 | 8.6 Million USD | 2.93% |
| 2008 FY | 35.07 Million USD | 24.98% |
| 2007 Q2 | 7.38 Million USD | 25.02% |
| 2007 Q1 | 5.9 Million USD | -2.38% |
| 2007 Q4 | 7.43 Million USD | 1.3% |
| 2007 Q3 | 7.33 Million USD | -0.62% |
| 2007 FY | 28.06 Million USD | 57.52% |
| 2006 FY | 17.81 Million USD | 66.66% |
| 2006 Q1 | 1.38 Million USD | 0.0% |
| 2006 Q4 | 6.05 Million USD | 5.07% |
| 2006 Q2 | 4.61 Million USD | 232.8% |
| 2006 Q3 | 5.75 Million USD | 24.69% |
| 2005 FY | 10.68 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 93.021% |
| Embecta Corp. | 1.12 Billion USD | 96.471% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 91.875% |
| Dynavax Technologies Corporation | 232.28 Million USD | 82.972% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 66.001% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 94.14% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 21.807% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -64.167% |
| SCYNEXIS, Inc. | 140.14 Million USD | 71.777% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -1950.95% |
| Cosmos Health Inc. | 53.37 Million USD | 25.9% |
| Journey Medical Corporation | 79.18 Million USD | 50.048% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -64.167% |
| Safety Shot Inc | 202.67 Thousand USD | -19415.719% |
| Alpha Teknova, Inc. | 36.68 Million USD | -7.82% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 91.483% |
| Bright Green Corporation | 401.49 Thousand USD | -9751.406% |
| Procaps Group, S.A. | 409.92 Million USD | 90.351% |
| Theratechnologies Inc. | 81.76 Million USD | 51.626% |
| Harrow Health, Inc. | 130.19 Million USD | 69.62% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -210.581% |
| Biofrontera Inc. | 34.07 Million USD | -16.088% |
| DURECT Corporation | 8.54 Million USD | -362.711% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 93.49% |
| Cronos Group Inc. | 88.84 Million USD | 55.479% |
| OptiNose, Inc. | 70.98 Million USD | 44.282% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 91.066% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -507.269% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 90.868% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -222.916% |
| Radius Health, Inc. | 2.88 Billion USD | 98.628% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -22.42% |
| ProPhase Labs, Inc. | 44.38 Million USD | 10.886% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 96.113% |
| Procaps Group S.A. | 409.92 Million USD | 90.351% |
| Alvotech | 91.43 Million USD | 56.742% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -2937.827% |
| Viatris Inc. | 15.42 Billion USD | 99.744% |
| Rockwell Medical, Inc. | 83.61 Million USD | 52.695% |
| Aytu BioPharma, Inc. | 81 Million USD | 51.171% |
| SIGA Technologies, Inc. | 139.91 Million USD | 71.731% |
| Tilray Brands, Inc. | 788.94 Million USD | 94.987% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 69.162% |
| Shineco, Inc. | 9.8 Million USD | -303.521% |
| PetIQ, Inc. | 1.1 Billion USD | 96.411% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -329504.225% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 97.904% |
| Alimera Sciences, Inc. | 80.75 Million USD | 51.021% |
| Silver Spike Investment Corp. | 11.72 Million USD | -237.417% |
| Assertio Holdings, Inc. | 152.06 Million USD | 73.99% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -579.318% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -127.091% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -3574.5% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -41.446% |
| Hempacco Co., Inc. | 4.04 Million USD | -877.658% |
| Talphera, Inc. | 651 Thousand USD | -5975.654% |
| Alvotech | 91.43 Million USD | 56.742% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 87.507% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 96.949% |
| Currenc Group, Inc. | 53.25 Million USD | 25.73% |
| Kamada Ltd. | 144.75 Million USD | 72.677% |
| Indivior PLC | 1.09 Billion USD | 96.381% |
| Evoke Pharma, Inc. | 5.18 Million USD | -663.469% |
| Flora Growth Corp. | 76.07 Million USD | 48.006% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -3574.5% |
| Evolus, Inc. | 202.08 Million USD | 80.428% |
| HUTCHMED (China) Limited | 837.99 Million USD | 95.28% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 93.862% |
| Akanda Corp. | 2.16 Million USD | -1731.091% |